Aethlon Medical reported Q2 2024 net loss of $2.8M compared to $3.0M in Q2 2023, with operating expenses decreasing 8.6% to $2.9M. The company successfully raised $5.4M through a public offering and warrant exercises in May-June 2024, ending the quarter with $6.9M cash. Professional fees decreased by $562K while payroll expenses increased by $181K due to separation costs.The company has made significant progress in its cancer clinical trials, with two patients at Royal Adelaide Hospital in Australia successfully completing screening and advancing to the run-in period. The trials are evaluating the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. Ethics committee approvals have been received for multiple sites in Australia and India.Management changes include the appointment of James B...Show More

Aethlon Medical reported Q2 2024 net loss of $2.8M compared to $3.0M in Q2 2023, with operating expenses decreasing 8.6% to $2.9M. The company successfully raised $5.4M through a public offering and warrant exercises in May-June 2024, ending the quarter with $6.9M cash. Professional fees decreased by $562K while payroll expenses increased by $181K due to separation costs.The company has made significant progress in its cancer clinical trials, with two patients at Royal Adelaide Hospital in Australia successfully completing screening and advancing to the run-in period. The trials are evaluating the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment. Ethics committee approvals have been received for multiple sites in Australia and India.Management changes include the appointment of James B. Frakes as permanent CEO while retaining his CFO role, and the termination of Guy Cipriani as COO. The company notes that existing cash is insufficient for 12-month operations and additional financing will be required. Clinical trial expenses are expected to increase as the company advances its oncology trials and manufacturing of Hemopurifiers.